The market is showcasing evident potential in the mentioned forecasting period. Ophthalmology is the branch of medicine associated with the treatment of eye defects and diseases. With the recent advancements in genetics and stem cell biology, the mechanisms of many ophthalmic diseases are being revealed progressively.

Ophthalmology Therapeutics Market was worth $25.72 billion in 2018 and estimated to be growing at a CAGR of 7.4%, to reach $36.75 billion by 2023.

KEY POINTS OF TOC:

Market Segmentation                                              
                5.1 By Indication                              

                                5.1.1 Glaucoma

                                5.1.2 Dry Eye Syndrome

                                5.1.3 Diabetic Retinopathy         

                                5.1.4 Retinal Vein Occlusion        

                                5.1.5 Age-Related Macular Degeneration (AMD)

                                5.1.6 Macular Edema    

                                5.1.7 Allergic Conjunctivitis       

Request sample report at   https://www.marketdataforecast.com/market-reports/global-ophthalmology-therapeutics-market-1106/request-sample

                5.2 By End User               

                                5.2.1 Hospitals  

                                5.2.2 Eye Clinics

                                5.2.3 Diagnostic Centers              

                                5.2.4 Patients   

Browse full report at https://www.marketdataforecast.com/market-reports/global-ophthalmology-therapeutics-market-1106/

On the basis of geography, the global market is analysed under various regions namely North America, Europe, Asia-Pacific, Latin America and Middle-East.

Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc. and Roche are the major companies in the market accounting for a share of approximately 70%. Other major companies covered in the report are Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals.